Supplementary Information file for the article:
Hypertension and kidneys: unraveling complex
molecular mechanisms underlying
hypertensive renal damage
Silvia Mennuni 1, Speranza Rubattu 1,2, Giorgia Pierelli 1, Giuliano Tocci 2, Claudia Fofi 3, Massimo
Volpe 1,2
1) Dept. Clinical and Molecular Medicine, School of Medicine and Psychology, University
Sapienza of Rome, Ospedale S. Andrea, Rome;
2) IRCCS Neuromed, Pozzilli, Isernia;
3) Nephrology and Dialysis Unit, School of Medicine and Psychology, University Sapienza of
Rome, Ospedale S. Andrea, Rome, all from Italy.
Running title: hypertensive renal damage
Correspondence to:
Massimo Volpe M.D., Speranza Rubattu, MD.
Dep. of Clinical and Molecular Medicine
School of Medicine and Psychology
Sapienza University, S.Andrea Hospital, Rome;
IRCCS Neuromed, Pozzilli (Is), Italy
e-mail: massimo.volpe@uniroma1.it
rubattu.speranza@neuromed.it;
This file is provided to contain all references quoted in the Table 1 of the article that could not be
included in the main text due to space constraints.
1. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M et al. Effect of the
angiotensin converting- enzyme inhibitor benazepril on the progression of chronic renal
insufficiency.
The
Angiotensin-Converting
Enzyme
Inhibition
in
Progressive
Renal
Insufficiency study group. N Engl J Med 1996; 334: 939–945.
2. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised
placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of
terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–1863.
3. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of
macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:
713–720.
4. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M et al. Renoprotective
properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Lancet 1999; 354: 359–364.
5. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP et al. Effect of ramipril vs
amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J
Am Med Assoc 2001; 285: 2719–2728.
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of
losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 2001; 345:861–69.
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of
the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N Engl J Med 2001; 345: 851–860.
2
8. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al.
Does albuminuria predict cardiovascular outcome on treatment with losartan versus
atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J
Hypertens. 2004; 22:1805-11.
9. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V et al. Bergamo Nephrologic
Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type
2 diabetes. N Engl J Med 2004; 351: 1941-1951.
10. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR et al. Efficacy and safety of
benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
11. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al. ONTARGET
investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk
(the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;
372: 547-553.
12. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WPTM, Buskens E, Beek FJA et al. Stent placement
in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized
trial. Ann Intern Med 2009; 150: 840-848.
13. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K et al. ACCOMPLISH Trial
investigators Renal outcomes with different fixed-dose combination therapies in patients with
hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary
analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
3